PERMEPSY is a three-year project composed of 5 clinical partners from 5 different countries (Spain, Germany, France, Poland and Chile) and one technological team (Spain). The aim of PERMEPSY (Personalised Medicine approach to psychological treatment for Psychosis) is to offer personalised delivery of Metacognitive Training (MCT) for people with psychosis. PERMEPSY members collaborate by reviewing the literature on the variables associated with better treatment response in psychosis and identifying key factors predicting MCT effectiveness. Moreover, we aim to analyse multimodal retrospective data from previous clinical trials using machine learning (ML) techniques and the variables identified via systematic reviews. The ML algorithm will inform the development of a prototype platform which will be made freely available to clinicians worldwide to aid their clinical decision-making when treating patients with psychosis. The platform will be validated with a pilot clinical trial with two arms, comparing classical MCT to a personalised delivery recommended by the platform, testing its predictive power.